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ABSTRACT
Raloxifene (RAL) and alendronate (ALN) improve the biomechanical properties of bone by different mechanisms. The goal here was to
investigate the effects of combination treatment of RAL and ALN on the biomechanical properties of vertebral bone. Six-month-old
Sprague-Dawley rats (n¼80) were randomized into five experimental groups (sham, OVX, OVXþRAL, OVXþALN, and
OVXþRALþALN; n¼16/group). Following euthanization, structural and derived material biomechanical properties of vertebral bodies
were assessed. Density and dynamic histomorphometric measurements were made on cancellous bone. The results demonstrate that
the structural biomechanical properties of vertebral bone are improved with the combination treatment. Stiffness and ultimate load of
the OVXþRAL and OVXþALN groups were significantly lower than those of sham animals, but the combination treatment with
RALþALN was not significantly different from sham. Furthermore, the OVXþRALþALN group was the only agent-treated group in
which the ultimate load was significantly higher than that in OVX animals (p<.05). Cancellous bone fractional volume (BV/TVcanc) and
bone mineral density (aBMD) also were improved with the combination treatment. BV/TVcanc of the OVXþRALþALN group was 6.7%
and 8.7% greater than that of the OVXþRAL (p<.05) and OVXþALN (p<.05) groups, respectively. Areal BMD of the OVXþRAL or
OVXþALN groups was not significantly different from that in OVX animals, but the value in animals undergoing combination treatment
was significantly higher than that in OVX or OVXþRAL animals alone and not significantly different from that in sham-operated animals.
Turnover rates of both the RALþALN and ALN alone groups were lower than in the RAL-treated alone group (p<.05). We conclude that
the combination treatment of raloxifene and alendronate has beneficial effects on bone volume, resulting in improvement in the
structural properties of vertebral bone.  2011 American Society for Bone and Mineral Research.
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Introduction
R
aloxifene (RAL), a selective estrogen receptor modulator
(SERM), and alendronate (ALN), a bisphosphonate, reduce
vertebral fracture risk by nearly the same extent despite variable
effects on bone mineral density (BMD).
(1–3) Compared with
placebo,RALtreatmentsuppressedboneturnoverandincreased
lumbar spine BMD by about half as much as ALN, but both
agents produced similar reductions in vertebral fracture risk.
(1–7)
The contribution of the increase in BMD accounts for only 4% of
the vertebral fracture reduction with RAL compared with 17%
with ALN.
(1,3,6,7) These data suggest that RAL and ALN improve
the biomechanical properties of vertebral bone by different
mechanisms.
Consistent with the clinical data, previous studies in an animal
model have shown that the clinical dose of RAL alters the
properties of canine vertebral bone in ways that differ from
bisphosphonates.
(3,8–11) ALN has negative effects on the derived
material properties (structural properties normalized by bone
geometry and fractional bone volume), but these negative
effects arecounteractedbyanincreaseinbonevolumesuchthat
there is no deterioration of the biomechanical properties at the
structural level.
(11) On the other hand, RAL does not increase
bone volume as much as ALN but improves the biomechanical
properties of bone by having positive effects on the derived
material properties.
(9) Since treatment with ALN is extending
beyond a decade in some patients, the potential negative effects
of ALN on the material properties could override the beneficial
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270effects of the increase in bone volume, leading to an impairment
ofthebiomechanicalpropertiesatthestructural level.Treatment
with both RAL and ALN (RALþALN) could offset part or all of
the deterioration in bone’s material properties that may be
associated with ALN and concomitantly increase BMD.
Johnell and colleagues
(12) investigated the additive effects of
RAL and ALN on BMD and biochemical markers of bone turnover
in postmenopausal women with osteoporosis. They found that
treatment with both RAL and ALN results in a greater BMD
increment at the femoral neck than did monotherapy with either
agent.
(12) Although BMD at the lumbar spine of the patients who
were treated with RALþALN was different only from those
treated with RAL alone, the authors concluded that the effects of
RALandALNonBMDareindependentandadditive.
(12)However,
the effects of RALþALN on the structural and material
biomechanical properties of bone were not determined in that
study.
The goal of this study was to investigate the additive effects of
RAL and ALN on vertebral bone in an estrogen-deficient animal
model. We hypothesized that the combination of RAL and ALN
will improve bone’s structural properties more than each agent
alone by allowing the ALN-induced increase in bone volume but
preventing the negative effects of this bisphosphonate on
bone’s derived material properties by cotreatment with RAL.
Materials and Methods
Animals
Eighty-six-month-old Sprague-Dawley rats were obtained from
Harlan Laboratories (Indianapolis, IN, USA) and randomized into
five experimental groups (sham, OVX, OVXþRAL, OVXþALN,
and OVXþRALþALN; n¼16/group). All rats except those in the
sham-operated group were subjected to bilateral ovariectomy.
Compound administration was initiated after an acclimation
period of 17 days following ovariectomy. RAL (0.5mg/kg/day),
ALN (1.0mg/kg/day), RAL (0.5mg/kg/day)þALN (1.0mg/kg/day),
or daily saline vehicle (in equivalent volume to the drug
treatments) were given subcutaneously. The doses of RAL
(0.5mg/kg/day) and ALN (1.0mg/kg/day) approximate the
clinical treatment dose for postmenopausal women.
(3,13,14)
ALN was purchased from Sigma-Aldrich (St Louis, MO, USA)
and RAL was provided by Eli Lilly and Co. (Indianapolis, IN, USA).
All animals were pair housed under standard laboratory
conditions and had free access to food (2014 Teklad Global
14%ProteinRodent Maintenance Diet,Indianapolis, IN, USA) and
water. One rat in the OVXþALN group was removed from the
study owing to illness. Animals were euthanized 16 weeks after
the initiation of treatment. All rats were double-labeled with
calcein (10mg/kg of body weight, i.p.) with a 7-day interlabel
period and a 3-day period for washout (ie, 1-7-1-3). Following
euthanization, the lumbar vertebrae and tibias were collected
and stored. All procedures were approved by the Indiana
University School of Medicine Animal Care and Use Committee.
Densitometry
Whole L6 vertebrae were scanned by micro–computed tomo-
graphy (mCT; mCT40, Scanco Medical, Bassersdorf, Switzerland)
to determine vertebral cross-sectional area, bone fractional
volume, and trabecular microarchitecture. Prior to scanning, the
posterior elements and transverse processes were removed by a
bone cutter. The end plates also were removed using a low-
speed diamond saw (Isomet 1000 Precision Saw, Beuhler, Lake
Bluff, IL, USA). Removal of the cranial/caudal endplates was done
such that the bone surfaces were parallel for mechanical
testing.
(15) Four L6 vertebrae (sham, n¼1; ALN, n¼2;
OVXþRALþALN, n¼1) were substituted with the correspond-
ing L5 vertebrae because they fractured during the cutting
process. The specimens were imaged at 12-mm resolution, 55-
kVp voltage, and 145mA. A representative vertebral cross-
sectional area (CSA, mm
2) value for each vertebra was calculated
as the average of the CSA measured at three different locations
(25%, 50%, and 75% of total vertebral height).
(15) Bone fractional
volume and trabecular microarchitecture were analyzed (s¼0.8,
support¼2) in a 1.2-mm region directly above the caudal
growth plate. This region was selected to avoid any errors
introduced by the anterior venous foramen. The following
parameters were obtained: whole vertebra (cancellous and
corticalbone)fractionalvolume(BV/TVwhole vert),cancellousbone
fractional volume (BV/TVcanc), trabecular thickness (Tb.Th, mm),
trabecular number (Tb.N, mm
 1), trabecular separation (Tb.Sp,
mm), and structural model index (SMI). For the cancellous bone
parameter (BV/TVcanc, Tb.Th, Tb.N, Tb.Sp, and SMI) analysis, the
cortical shell was removed using an adapted segmentation
algorithm ‘‘dual threshold’’.
(16)
Following mCT scans, areal bone mineral density (aBMD,
g/cm
2) of the lumbar vertebrae was assessed using a PIXImus II
densitometer (Lunar Corp., Madison, WI, USA). The specimens
were scanned in the anteroposterior direction (ie, the posterior
side was placed down).
(17)
Biomechanical testing
Biomechanical properties were obtained on the same vertebrae
that were analyzed for densitometry. Testing was performed
under uniaxial compression loading (0.5mm/min) on a servo
hydraulic testing machine (858 Mini Bionix II, MTS Corp., Eden
Prairie, MN, USA).
(17) Load-displacement data were recorded at a
frequency of 100Hz. The specimens were glued to the
compression platens during testing. Structural (extrinsic) proper-
ties included stiffness (slope of the linear portion of load-
displacement curve S, N/mm), ultimate load (maximum load
obtained during testing UL, N), and work to failure (area under
the load-displacement curve up to the ultimate load W, mJ).
Derived material (intrinsic) properties (normalized stiffness nS,
normalized ultimate load nUL, normalized work to failure nW)
were calculated by normalizing the structural properties to bone
geometry and whole vertebra fractional volume using the
following equations
(15,18):
nS ¼½ S  ð h=CSAÞ =ðBV=TVwholevertÞ
nUL ¼ð UL=CSAÞ=ðBV=TVwholevertÞ
nW ¼½ W=ðh   CSAÞ =ðBV=TVwholevertÞ
where h is the specimen height, measured using digital calipers
prior to mechanical testing.
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Histologic measures were obtained on cancellous bone of the
right proximal tibia to assess the effectiveness of the drug
treatments. The right tibias were placed in 10% phosphate-
buffered formalin for 3 days and then transferred to 70% ethanol
untilprocessing.
(15,18)Thespecimensweredehydratedthrougha
graded series of ethanols (70% to 100%) using an automatic
tissue processor (Shandon/Lipshaw, Pittsburgh, PA, USA).
(15,18)
Following dehydration, the tibias were cleared with xylenol and
embedded in methyl methacrylate (MMA; Sigma Aldrich, St
Louis, MO, USA), as described previously.
(15) Transverse sections
from theproximaltibiawerecutat4mmthickusingamicrotome
(Leica RM2253, Richmond, IL, USA) and left unstained for
dynamic histomorphometry measures. The sections were
mounted on glass slides using Eukitt’s glue (Electron Microscopy
Sciences, Hatfield, PA, USA).
Dynamic histomorphometric measurements were performed
via a semiautomatic analysis system (Bioquant OSTEO 7.20.10,
Bioquant Image Analysis Co., Nashville, TN, USA) connected to an
epifluorescence microscope (Nikon Optiphot 2 Microscope,
Nikon, Melville, NY, USA).
(15) A sampling region of approximately
8mm
2 was examined from the right proximal tibia. The
measurements were done in the secondary spongiosa, 1mm
distal from the end plate. Dynamic histomorphometric para-
meters included mineralizing surface (MS/BS), mineral apposi-
tion rate (MAR, mm/day), and bone formation rate (BFR/BS,
mm
3/mm
2/year). Two specimens in the OVXþRALþALN group
and one specimen in the OVXþRAL group did not have double
label and were assigned a value of 0.3mm/day for MAR.
(19,20)
Dynamic variables were measured and calculated in accordance
with ASBMR recommended standards.
(21)
Statistics
The differences among the groups (sham, OVX, OVXþRAL,
OVXþALN, and OVXþRALþALN) were examined using one-
way analysis of variance (ANOVA) tests following Anderson-
Darling normality tests. When a significant overall F value
was present (p<.05), Fisher’s protected least-significant-
difference (PLSD) post hoc tests were used to compare
differences between individual group means. For variables
violating the normality assumption, Kruskal-Wallis tests were
used. When the Kruskal-Wallis test revealed a significant
difference (p<.05), it was followed by Mann-Whitney pairwise
comparisons between individual group medians. For all tests,
p<.05 was considered statistically significant. MINITAB 15
software (Minitab, Inc., State College, PA, USA) was used for
all the statistical analyses.
Results
The combined treatment of RAL and ALN had beneficial effects
on the structural biomechanical properties of vertebral bone.
Stiffness and ultimate load of the OVXþRALþALN group were
not significantly different than those of the sham-operated
group (Fig. 1A, B). In contrast, when either agent was
administered alone (OVXþRAL or OVXþALN) stiffness and
ultimate load were significantly lower than sham (Fig. 1A, B;
p<.05). Furthermore, the OVXþRALþALN group was the only
agent-treated group in which the ultimate load was significantly
higher (þ23.8%) than that of OVX (Fig. 1B; p<.05). No
Fig. 1. Structural biomechanical properties of the vertebral body follow-
ing treatment: (a) Stiffness S (pANOVA¼.043); (b) ultimate load UL
(pANOVA¼.004); (c) Work to failure W (pKruskal-Wallis¼.686). (A) Signifi-
cantly different from sham; (B) significantly different from OVX. Data are
presented as SE mean.
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material biomechanical properties were found (Table 1).
The differences in structural properties were associated with
changesinfractionalbonevolumeandbonemineraldensity.BV/
TVcanc of the RALþALN group was 6.7% and 8.7% higher than
that of the RAL (p<.05) and ALN (p<.05) groups, respectively
(Fig. 2A). Unlike both the OVXþALN and OVXþRAL groups,
which had significantly lower aBMD than sham (Fig. 2B; p<.05),
theOVXþRALþALN groupaBMD wasnot significantlydifferent
from sham (Fig. 2B). The OVXþRALþALN group had a 6.3%
higher aBMD than the OVXþRAL group (Fig. 2B; p<.05).
The combined treatment also resulted in positive effects on
cancellous bone microarchitecture. Tb.N and Tb.Sp of the
combination treatment group were not significantly different
from those of the sham group (Table 2). On the other hand, both
the OVXþRAL and the OVXþALN groups had a lower Tb.N and
greater Tb.Sp than sham (Table 2; p<.05). The RALþALN
treatment significantly increased Tb.N (Table 2; þ7%, p<.05)
and decreased Tb.Sp (Table 2;  8.6%, p<.05) relative to
treatment with RAL alone. In addition, SMI of the
OVXþRALþALN group was 40.3% lower (more negative) than
that of the OVXþALN group (Table 2; p<.05), suggesting that
the trabecular plates of the OVXþRALþALN group contain
more closed cavities between trabeculae.
(22) No beneficial effect
in Tb.Th with the combination treatment compared with the
monotherapy treatments was detected.
Dynamic histomorphometric measures revealed differences
when the two agents were combined. Bone formation rate
(surface-based remodeling rate) of the OVXþRALþALN group
was 68.5% lower than that of the OVXþRAL group (p<.05;
Table 3). The difference in bone turnover rate between the
OVXþRALþALN and OVXþRAL groups was achieved mainly
by a lower MS/BS (Table 3;  65.1%, p<.05), which was
suppressed about 25% more than with ALN alone.
Discussion
Following 16 weeks of dosing, the combination of RAL and ALN
increased bone volume more than either agent administered
alone, resulting in an improvement in the extrinsic biomecha-
nical properties. The results suggest that for osteoporotic
patients who are at a higher fracture risk owing to elevated bone
loss, the combined treatment of RAL and ALN may be more
efficacious than treatment with RAL or ALN alone. To our
knowledge, this is the first study to report the effects of
combining these two different treatment regimens on bone
volume and biomechanical properties.
In acanine model, it hasbeen shown that ALNand RAL improve
the biomechanical properties of bone by different mechanisms.
Compared with vehicle-treated animals, treatment with ALN had
negative effects on the derived material properties, but these
negativeeffects were counteracted byan increase in bone volume
such that there was no deterioration to bone’s structural
properties.
(11) On the other hand, treatment with RAL improved
the derived material properties compared with vehicle-treated
animals but did not increase bone volume as much as ALN.
(9)
Consistent with these data,Allen and colleagues
(3) have found that
compared with treatment with ALN, treatment with RAL resulted
in an improvement in the derived material properties. We
Table 1. Derived Material Properties of Vertebral Bone Following Treatment
Sham OVX OVXþRAL OVXþALN OVXþRALþALN p Value
nS (GPa) 5.69 0.59 5.61 0.57 4.69 0.43 5.02 0.58 4.92 0.48 pKruskal-Wallis¼.633
nUL (MPa) 69.06 4.39 68.21 3.96 61.79 4.11 68.09 3.45 67.08 2.24 pKruskal-Wallis¼.611
nW (MPa) 0.67 0.07 0.69 0.04 0.79 0.08 0.71 0.08 0.74 0.08 pKruskal-Wallis¼.599
Data are presented as SE mean. nS¼normalized stiffness; nUL¼normalized ultimate load; nW¼normalizd work to fracture.
Fig. 2. Bone volume measurements following treatment: (a) Cancellous bone fractional volume (BV/TVcanc)(pANOVA<.001); (b) aBMD of the vertebral
body (pANOVA<.001). (A) Significantly different from sham; (B) significantly different from OVX; (C) significantly different from OVXþRAL; (D) significantly
different from OVXþALN. Data are presented as SE mean.
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improve bone’s structural properties more than each agent alone
by allowing the ALN-induced increase in bone volume and
preventing the negative effects of ALN on bone’s derived material
properties by cotreatment with RAL. The results reported here
show that compared with the OVX group, the treatment with RAL
or ALN alone did not result in significant changes in the derived
material properties (Table 1). Thus the additive positive effects of
the interaction between RAL and ALN on the structural properties
ofvertebralbonefoundherearenotbecausethecotreatmentwith
RAL had prevented the negative effects of ALN on the derived
material properties. One possible explanation for the differences in
the derived material properties between the canine study and this
investigation could be related to the treatment duration. In the
study of Allen and colleagues,
(3) the dogs were treated for 1 year,
whereas the rats in our study were treated for 16 weeks. Although
the number of remodeling cycles during the treatment duration in
these two studies is almost the same,
(23–25) the mean age of the
bone matrix following treatment will be different in these animal
models. This is so because the mean age of the bone matrix is a
function of both the treatment duration and the number of
remodelingcyclesduringthetreatment.Themeanageofthebone
matrix is deemed to be associated with changes in the tissue
matrix properties (ie, bone microstructure and ultrastructure),
which, in turn, have a direct effect on bone’s material proper-
ties.
(8,26,27) Since rodents have a short life span compared with
larger animals, future studies investigating the long term additive
effects of RAL and ALN on the material properties of bone should
be done in a large animal model.
In this study, we found significant declines in vertebral
microarchitecture and a significant increase in BFR/BS in OVX
animals compared with the sham group, showing the effective-
ness of the ovariectomy. However, we did not find significant
differencesinanyofthederivedmaterialpropertiesbetweenthe
sham and OVX groups. Although this could be a function of the
age of the animals and the duration of treatment, a more likely
explanation is that ovariectomy alters structural properties of
vertebral trabecular bone but does not significantly change the
properties of the bone tissue itself.
The results of this investigation are consistent with those of
Johnell and colleagues,
(12) who showed that in postmenopausal
women with osteoporosis, the effects of RAL and ALN on BMD
are independent and additive when given in combination.
RALþALN produced a greater incremental increase in BMD at
the femoral neck than each agent alone.
(12) The lumbar spine
BMD ofthe RALþALNgroup wasroughlythesameas inthe ALN
alone group but was significantly higher than in the RAL alone
group.
(12) They also reported that patients who received
RALþALN or ALN alone treatment had similar levels of bone
turnover but lower levels than those who received RAL.
(12) We
demonstrated that RALþALN treatment resulted in a higher
cancellousfractionalbonevolumethanmonotherapywitheither
RAL or ALN alone. The changes in the lumbar vertebral aBMD
reported here were similar to the changes in lumbar spine BMD
reported by Johnell and colleagues
(12) (Fig. 2B). Furthermore, we
found that the turnover rate of the animals treated with
RALþALN reached significance only when compared with those
treated with RAL alone (Table 3).
It is noteworthy that although aBMD is often used as a clinical
surrogate for bone strength, it is a poor indicator of bone
density.
(1,6,7) This is so because aBMD provides a low-resolution
2D projection of bone mineral content and cannot differentiate
whether thechangesoccurincancellousorcorticalbone.
(28,29)In
contrast, BV/TVcanc, as measured in this investigation, is a high-
resolution 3D assessment of bone density and is specific to
cancellous bone.
(28,29) The effects of antiremodeling agents on
bone density are more pronounced in cancellous bone.
(20) A
high-resolution imaging modality is needed to detect such
Table 2. Cancellous Bone Microarchitecture Parameters Following Treatment
Sham OVX OVXþRAL OVXþALN OVXþRALþALN p Value
Tb.Th. (mm) 90.39 1.20 74.23 0.90
a 82.79 1.12
a,b 80.28 1.33
a,b 82.83 1.33
a,b pANOVA<.001
Tb.N. (mm
 1) 5.50 0.07 4.31 0.07
a 4.97 0.09
a,b 5.16 0.04
a,b 5.32 0.10
b,c pANOVA<.001
Tb.Sp. (mm) 162.74 3.07 223.08 3.76
a 186.38 4.39
a,b 177.85 2.23
a,b 170.39 3.86
b,c pKruskal-Wallis<.001
SMI  2.31 0.16  0.22 0.06
a  1.41 0.09
a,b  1.19 0.09
a,b  1.67 0.14
a,b,d pANOVA<.001
Data are presented as SE mean. Tb.Th¼trabecular thickness; Tb.N¼trabecular number; Tb.Sp¼trabecular separation; SMI¼structural model index.
aSignificantly different from sham.
bSignificantly different from OVX.
cSignificantly different from OVXþRAL.
dSignificantly different from OVXþALN.
Table 3. Cancellous Bone Dynamic Histomorphometric Parameters Following Treatment
Sham OVX OVXþRAL OVXþALN OVXþRALþALN p Value
MS/BS % 8.86 0.82 19.15 1.52
a 13.11 1.36
a,b 5.96 1.16
a,b,c 4.57 0.33
a,b,c pKruskal-Wallis<.001
MAR (mm/day) 1.12 0.04 1.03 0.04 1.00 0.07 0.77 0.04
a,b,c 0.85 0.09
a,b pANOVA<.001
BFR/BS (mm
3/mm
2/year) 36.0 3.4 71.9 5.9
a 46.3 4.7
b 18.0 0.7
a,b,c 14.6 1.9
a,b,c pKruskal-Wallis<.001
Data are presented as SE mean. MS/BS %¼mineralizing surface; MAR¼mineral apposition rate; BFR/BS¼bone formation rate.
aSignificantly different from sham.
bSignificantly different from OVX.
cSignificantly different from OVXþRAL.
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evaluating the efficacy of the combination treatment.
ThecombineduseofRALþALNalsoledtoanimprovementin
trabecular number and separation more than could be achieved
with either agent alone (Table 2). SMI of the OVXþRALþALN
group was more negative than that of the ALN group. As
described by Mastbergen and colleagues,
(22) a more negative
SMI suggests that the trabecular plates contain more closed
cavities between trabeculae.
(22) The conversion from open to
closed trabecular plates is related to an increase in bone volume
and trabecular thickness.
(22) Taken together, the addition of RAL
to an ALN regimen may enhance bone microarchitecture, one
measure of bone quality, substantially in osteoporotic patients.
This study has various limitations. First, the derived material
propertiesreportedhereareonlyanestimateofthetruematerial
properties. This is so because it is not possible to fully take into
account bone geometry, fractional volume, and microarchitec-
ture in calculating the derived material parameters. Second,
four L6 vertebrae were substituted with the corresponding L5
vertebrae because they fractured during the cutting process.
However, all the experimental values from each substituted
vertebra were within 3 SD of the mean values for L5 vertebrae
within their respective groups. Third, the histomorphometric
analysis of cancellous bone was done on the proximal tibia,
whereas the biomechanical properties were obtained from the
vertebra. The goal of calculating the histomorphometric
parameters was to assess the effect of RALþALN treatment
on the turnover rate of cancellous bone. Because the effects of
ovariectomy occur earlier in the proximal tibia than verte-
bra,
(30,31) we chose to conduct the histomorphometric analysis
on the proximal tibia. We expect, though, that the effects of
RALþALN on turnover rate will be similar among different
cancellous bone sites. Furthermore, the changes in bone
turnover rate found in this investigation are in good agreement
with clinical data.
(12)
In conclusion, in an ovariectomized adult rat model, which is
an established model for estrogen-deficiency osteoporosis, we
showed that the combination of RAL and ALN has greater
beneficial effects on bone volume and biomechanical properties
of vertebral bone compared with either agent alone. The
findings of this work provide new insight into the effects of
combining two different osteoporosis treatment modalities on
bone fragility. Further studies should be done in large animal
models to ascertain the positive effects of the combination
treatment of RAL and ALN on vertebral bone observed here.
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